111 results about "Human type" patented technology

The present invention provides an animation creation program whereby the posture of a structure comprising a plurality of links can be determined by means of a simpler and easer operation. In accordance with the movement of one link in the structure comprising a plurality of links, the animation creation program of the present invention automatically determines the spatial positions of the other links of the structure so that the structure retains a posture that is as natural as possible. The animation creation program of the present invention uses, for example, inverse kinematics computation that is a computation method for controlling a human-type robot (humanoid) and is based on a matrix known as a Jacobian and the inverse matrix thereof which is known as the Singularity-Robust Inverse (SR-Inverse). By using this computation method in an animation creation program, in the creation of an animation of a structure comprising a plurality of links, it is possible, when moving one link of a structure displayed on a screen, to automatically determine the positions of the other links of the structure so that the posture of the structure as a whole does not become unnatural, and to create an animation of the structure comprising a plurality of links by means of a simpler and easer operation.

The present invention relates to a method for the production and the selection of human or chimaeric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through the human type IIB receptors of IgG (FcgammaRIIB/CD32).

Hydroxyapatite (HA)-binding peptides are selected using combinatorial phage library display. Pseudo-repetitive consensus amino acid sequences possessing periodic hydroxyl side chains in every two or three amino acid sequences are obtained. These sequences resemble the (Gly-Pro-Hyp)_x repeat of human type I collagen, a major component of extracellular matrices of natural bone. A consistent presence of basic amino acid residues is also observed. The peptides are synthesized by the solid-phase synthetic method and then used for template-driven HA-mineralization. Microscopy reveal that the peptides template the growth of polycrystalline HA crystals ˜40 nm in size.

The invention relates to an amino acid sequence of a fusion protein for treating human type I and type II diabetes, and a production method and an application thereof. The invention relates to a noninsulin diabetes treatment method which can be used for avoiding insulin resistance. The fusion protein related to the invention is formed by fusing an insulin mimetic peptide and an IgG-Fc or IgG-Fc mutant through a connecting peptide, so that the in-vivo half-life of the insulin mimetic peptide can be prolonged remarkably while the blood sugar lowering activity of the insulin mimetic peptide is kept. The mutant of IgG-Fc can be used for further prolonging the in-vivo half-life of the fusion protein.

The invention provides a method for establishing a type 2 diabetes animal model. An animal is fed with a high-fat and high-sugar feed for a period of time, and the animal is drenched with alcohol with certain concentration at the same time. The attack process of human type 2 diabetes is simulated in the method; and the prepared animal model has typical characteristics of the type 2 diabetes such as high fasting blood glucose, high insulinemia, hyperlipidemia and impaired glucose tolerance, and is suitable for mechanism research of the type 2 diabetes and screening of a large quantity of medicaments.

The invention belongs to the technical field of article detection and specifically relates to a weak magnetic detection method which carries out detection by taking a weak magnetic field feature of a detected object as a basis. According to the technical scheme provided by the invention, the detected object can be distinguished according to concrete types comprising a human type, an eyeglass ornament type, a communication recording equipment type such as mobile phone earphones and the like, a key watch type, a controlled knife type and other types. Products further developed based on a basic principle of the method include yet are not confined to mobile phone detection doors, radiation-free metal safety check doors, package detectors, metal lossless flow detection devices and the like. On the basis that the type of the detected object is distinguished by use of the magnetic field feature of the detected object, the purpose of relevant detection is realized, and the rate of false alarm is substantially reduced.

The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and specifically inhibits the coagulation activity of human FVIII. ScFv display phage libraries, prepared by using scFv DNAs constructed by random combinations of immunoglobulin VH chain genes and VL chain genes from lymphocytes from hemophilia A patients, is reacted with FVIII immobilized to a solid phase via anti-FVIII monoclonal antibody, and scFv clones capable of binding to FVIII are cloned to reveal VH and VL chains of FVIII-specific antibody.

The invention discloses a method for producing a recombinant human type II collagen single chain by Pichia pastoris. The present invention provides a nucleotide sequence encoding the recombinant humantype II collagen single chain, the nucleotide sequence is shown as SEQ ID NO. 1, and a nucleotide sequence of the recombinant human type II collagen single chain coded by the nucleotide sequence SEQID NO. 1 is shown as SEQ ID NO.2. The recombinant human type II collagen single chain obtained according to the present invention comprises a full-length amino acid sequence of a mature human type IIcollagen alpha1 chain, which can effectively support the realization of the biological function of the type II collagen, and has good biological activity, an amino terminal and a carboxy terminal contain different affinity purification tags, which can realize effective purifying to obtain the full-length single-chain protein, and is also beneficial for the identification of collagen; and accordingto the expression characteristics of Pichia pastoris, the method systematically optimizes the gene sequence encoding the recombinant human type II collagen single chain, so that better expression inPichia pastoris is realized.

The invention provides a method for establishing an SD mouse fat and diabetes research model through diet and STZ induction. Through high-fat feed and STZ induction, the attacking characteristics of fat and diabetes of humans are induced, and an animal model for establishing pathogenesis of fat and type-2-diabetes caused by insulin resistance and partial defects of pancreatic beta cells is provided. Mice are divided into a normal control group, a fat group and a diabetes group, and each group has six SD male mice. The high-fat feed is adopted for feeding mice for eight weeks, a pure-fat insulin resistance model is induced, after the mice are fed with the high-fat feed for eight weeks, injection of STZ small doze in batch is conducted, and establishment of the diabetes animal model is induced. The method can better simulate the attacking characteristics of human type-2-diabetes caused by improper diet and enjoinment factors currently, and compared with other modeling, the method has better scientific significance of clinical and fundamental research combination.

The invention belongs to the field of biotech applications and relates to a multiplex fluorescence RT-PCR (reverse transcription-polymerase chain reaction) method including internal quality control and a kit for simultaneously detecting human type A and type B respiratory syncytial viruses and human metapneumoviruses. Specific primers and probes are designed for N genes, L genes and conserved sequences of the L genes of representive strains of the human type A and type B respiratory syncytial viruses and the human metapneumoviruses, the one-step multiplex fluorescence RT-PCR quick detection method including the internal quality control is simple and quick to operate, the tediousness of a conventional single fluorescence RT-PCR single-hole single-detection method is avoided, the operation program is simplified, the test cost is reduced, and strong technical support is provided for aspects of field detection, hygienic evaluation, clinical diagnosis and the like of the viruses by virtue of relatively high specificity, sensitivity, high efficiency and stability of the method.

The invention discloses a recombinant adenovirus and tetravalent adenovirus vaccine and a preparation method thereof. The tetravalent recombinant adenovirus vaccine contains a recombinant type 3 adenovirus strain, a recombinant type 7 adenovirus strain, a recombinant type 14 adenovirus strain and a recombinant type 55 adenovirus strain. The preparation method disclosed by the invention comprises the following steps: preparing recombinant shuttle plasmids containing hexon gene segments, and performing in-bacteria homologous recombination with a recombinant human type 3 adenovirus strain, thereby obtaining a recombinant adenoviral genome in which the hexon gene segments are replaced by type 7, type 14 and type 55; transfecting cells, rescuing to obtain recombinant human type 3, 7, 14 and 55 recombinant adenoviruses with different main capsid protein-hexon proteins; purifying, mixing according to the same protein content, and inactivating by using beta-propiolactone, thereby obtaining the tetravalent adenovirus vaccine. The tetravalent adenovirus vaccine is capable of inducing neutralizing antibody responses to four types of serotype adenoviruses, and the neutralizing titer is 500-1000.

The invention discloses a preparation method of an OLETF rat fasting blood-glucose elevation model, belonging to animal zoological medicinal models and feeds specially used for specifically animals. In the invention, an OLETF rat is feed by high-fat feed in 6-8 weeks, and the high-fat feed comprises the following raw materials in percentage by weight: 60-65 percent of standard feed, 10-12 percentof yolk powder, 10-12 percent of lard, 8-12 percent of sugar-free full-cream powder, 2-14 percent of cane sugar and 1-2 percent of water. The OLETF rat fed by the feed can simulate the morbidity process of human type II diabetes more and is good for the research of the type II diabetes; and the invention also shortens the time the OLETF rat develops into the diabetes, accelerates the molding, saves the experimental period and reduces the experimental cost.

An antibody or an antibody fragment is provided that is efficacious for treating allergic diseases in which IgE is involved. A human antibody and a fragment thereof to a receptor (FcεRI) having high affinity to Fc portion of IgE was obtained using phage antibody display technique. The human anti-IgE receptor antibody and a fragment thereof of the invention has an activity to inhibit the binding between IgE and IgE receptor and hence is expected to be useful as a medicament for treating allergic diseases caused by the binding between IgE and IgE receptor.

The invention provides recombinant human collagen and application thereof. An amino acid sequence encoding the recombinant human collagen is as shown in SEQ ID NO: 1, and the recombinant human collagen comprises an amino terminal affinity purification tag, a human type-I collagen alpha2 chain mature peptide chain and a carboxyl terminal affinity purification tag in sequence from the amino terminal. The recombinant human collagen has the advantages that by designing the specific affinity purification tags at both ends of the human type-I collagen alpha2 chain mature peptide chain, separation and purification and detection of the recombinant human collagen are easy; besides, the recombinant human collagen has a higher molecular weight and special physical and chemical properties, fermentation and expression are easy, the yield is high, and the application range is wide.

The invention discloses a dynein mosaic type recombinant human type-B adenovirus and a preparation method thereof. The skeleton of the dynein mosaic type recombinant human type-B adenovirus is a human type-B adenovirus genome, and a base sequence which encodes a receptor binding domain of dynein is a base sequence which encodes a corresponding domain of a human type-C adenovirus. By a molecular cloning method, Ad5-knob gene fragments are cloned and replaced to recombinant shuttle plasmids, in-vitro recombinant on the Ad5-knob gene fragments and a recombinant human type-3 adenovirus genome is realized, obtained knob gene fragments are replaced into type-5 recombinant human type-3 adenovirus genome, and therefore, dynein mosaic type recombinant human type-3 adenovirus rAd3-FK5 is obtained. The dynein mosaic type recombinant human type-3 adenovirus rAd3-FK5 can be infected with mouse primitive epithelial cells and golden hamster lung and kidney primitive cells in vitro, and the infection efficiency of the dynein mosaic type recombinant human type-3 adenovirus rAd3-FK5 is close to that of Ad5, and is much higher than that of a parent strain rAd3E, in golden hamster cells, significant copying exists, and the dynein mosaic type recombinant human type-B adenovirus can be used for small animal model research of human type-3 adenovirus vaccines and antiviral drug evaluation.

Association of Type II diabetes and a locus on chromosome 5q35 is disclosed. In particular, the gene SLIT-3 with this locus is shown by linkage analysis to be a susceptibility gene for Type II diabetes. Pathway targeting for drug delivery and diagnosis applications in identifying those have Type II diabetes or at risk of developing Type II diabetes, in particular those that are non-obese are described.

The invention provides modifiable amino acid loca in hypervariable regions of human type 3 adenovirus hexon. The modifiable loca are positioned in the hypervariable regions of the hexon and have at least one amino acid locus in a sequence shown as SEQ ID NO:1-4. The amino acid loca are positioned in hypervariable regions 1, 2, 5, and 7 of the human type 3 adenovirus hexon. The invention also provides the application of the modifiable amino acid loca to the show of extrinsic protein and the preparation of immunogen, medicaments and detection reagents. The modifiable amino acid loca lay the foundation for a virus show technology platform which is researched and developed by using a technology platform of modifiable extrinsic polypeptides in the hypervariable regions of the human type 3 adenovirus hexon as vaccines or antigens.

This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway proceed and the glycosylated peptide substrates are preferentially exported to the exterior of the cell or accumulated in the cell. In this invention i) the integrity of transiently and stably expressed ‘mucin’ type target peptides in plants cells has been determined and ii) mucin-type O-glycosylation has been established in plants by transient and stable introduction of a Pseudomonas aeruginosa C4-epimerase, the human polypeptide GalNAc-transferases T2 and T4 (GalNAc-T2 and T4) and various human target peptides or proteins. In the present invention GalNAc-T2 and -T4 have been used to produce a Tn cancer glycoform of MUC1.

The invention relates to a curcumin compound shown as the formula (1), a preparation method of the compound, and application of the compound as an inhibitor of type 1 11beta-hydroxysteroid dehydrogenase (11beta-HSD1) in a medicine for preventing and treating type 2 diabetes mellitus.